NanoViricides, Inc. (NYSE: NNVC) is a development stage company with a unique nanomedicine technology. The company is developing nanotechnology-based biomimetic anti-viral medicines called “nanoviricides.” So far, virus-specific nanoviricide drug candidates against five commercially important viral diseases: viz. seasonal and potentially-epidemic influenzas and bird flu, HIV/AIDS, cold sores and genital herpes infection, viral eye diseases, as well as dengue viruses, have demonstrated very high levels of effectiveness. For more information, visit the company’s website at www.nanoviricides.com.